Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's Syndrome

ClinicalTrials.gov ID: NCT02701985

Public ClinicalTrials.gov record NCT02701985. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 8, 2026, 4:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2A Study to Assess the Efficacy of RO5459072 in Patients With Primary Sjogren's Syndrome

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a randomized, double-blind, placebo-controlled, two-treatment arm, parallel-group study designed to evaluate the effects of RO5459072 treatment on disease activity and symptoms of Sjogren's syndrome in adult participants with moderate to severe primary Sjogren's syndrome. The total duration of the study for each participant will be approximately 18 weeks (including screening).

Study identification

NCT ID
NCT02701985
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Hoffmann-La Roche
Industry
Enrollment
75 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 4, 2016
Primary completion
Jul 9, 2017
Completion
Jul 9, 2017
Last update posted
Jul 31, 2018

2016 – 2017

United States locations

U.S. sites
12
U.S. states
10
U.S. cities
12
Facility City State ZIP Site status
Wallace Rheumatic Study Center Beverly Hills California 90211
Denver Arthritis Clinic Denver Colorado 80230-7127
Ochsner Clinic Foundation Baton Rouge Louisiana 70809
John Hopkins Bayview Medical Center Baltimore Maryland 21224
University Of Michigan Ann Arbor Michigan 48109
Winthrop University Hospital Mineola New York 11501
Shanahan Rheumatology & Immunology, PLLC Raleigh North Carolina 27617
MetroHealth System Cleveland Ohio 44109
Altoona Center For Clinical Research Duncansville Pennsylvania 16635
University of Pittsburgh Medical Center Pittsburgh Pennsylvania 15213
Clinical Research Center of Reading Wyomissing Pennsylvania 19610
Ramesh Gupta - PP Memphis Tennessee 38119

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 19 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02701985, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 31, 2018 · Synced Sep 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02701985 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →